MMJ BioPharma Cultivation Exposes DEA's Contradiction
A recently disclosed memorandum of understanding between the DEA and a registered marijuana cultivator has revealed a fatal flaw in America's cannabis research policy.
Newly uncovered DEA agreements confirm that the agency's own rules make it impossible for any company to legally produce pharmaceutical grade cannabis for FDA authorized clinical research.
MMJ BioPharma Cultivation has argued for years that the DEA's rules are a major obstacle to legitimate science, and this new information proves their case.
This contradiction has paralyzed legitimate science for nearly a decade, blocking access to FDA approved cannabis medicine.
Author's summary: DEA's rules hinder cannabis research.